Structure of C3b in complex with CRIg gives insights into regulation of complement activation

被引:183
作者
Wiesmann, Christian
Katschke, Kenneth J., Jr.
Yin, JianPing
Helmy, Karim Y.
Steffek, Micah
Fairbrother, Wayne J.
McCallum, Scott A.
Embuscado, Lizette
DeForge, Laura
Hass, Philip E.
van Lookeren Campagne, Menno
机构
[1] Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA
[4] Genentech Inc, Dept Assay Technol, San Francisco, CA 94080 USA
关键词
D O I
10.1038/nature05263
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The complement system is a key part of the innate immune system, and is required for clearance of pathogens from the bloodstream(1). After exposure to pathogens, the third component of the complement system, C3, is cleaved to C3b which, after recruitment of factor B, initiates formation of the alternative pathway convertases(2-4). CRIg, a complement receptor expressed on macrophages, binds to C3b and iC3b mediating phagocytosis of the particles 5, but it is unknown how CRIg selectively recognizes proteolytic C3-fragments and whether binding of CRIg to C3b inhibits convertase activation. Here we present the crystal structure of C3b in complex with CRIg and, using CRIg mutants, provide evidence that CRIg acts as an inhibitor of the alternative pathway of complement. The structure shows that activation of C3 induces major structural rearrangements, including a dramatic movement (>80 angstrom) of the thioester-bond-containing domain through which C3b attaches to pathogen surfaces. We show that CRIg is not only a phagocytic receptor, but also a potent inhibitor of the alternative pathway convertases. The structure provides insights into the complex macromolecular structural rearrangements that occur during complement activation and inhibition. Moreover, our structure - function studies relating the structural basis of complement activation and the means by which CRIg inhibits the convertases provide important clues to the development of therapeutics that target complement.
引用
收藏
页码:217 / 220
页数:4
相关论文
共 23 条
[1]  
FISHELSON Z, 1983, J BIOL CHEM, V258, P7411
[2]   The structure of bovine complement component 3 reveals the basis for thioester function [J].
Fredslund, Folmer ;
Jenner, Lasse ;
Husted, Use B. ;
Nyborg, Jens ;
Andersen, Gregers Rom ;
Sottrup-Jensen, Lars .
JOURNAL OF MOLECULAR BIOLOGY, 2006, 361 (01) :115-127
[3]  
Gadjeva M, 1998, J IMMUNOL, V161, P985
[4]   CRIg: A macrophage complement receptor required for phagocytosis of circulating pathogens [J].
Helmy, KY ;
Katschke, KJ ;
Gorgani, NN ;
Elliott, JM ;
Diehl, L ;
Scales, SJ ;
Ghilardi, N ;
Campagne, MV .
CELL, 2006, 124 (05) :915-927
[5]  
JANSSEN BJ, IN PRESS MOL IMMUNOL
[6]   Structures of complement component C3 provide insights into the function and evolution of immunity [J].
Janssen, BJC ;
Huizinga, EG ;
Raaijmakers, HCA ;
Roos, A ;
Daha, MR ;
Nilsson-Ekdahl, K ;
Nilsson, B ;
Gros, P .
NATURE, 2005, 437 (7058) :505-511
[7]  
Kostavasil I, 1997, J IMMUNOL, V158, P1763
[8]   Decay accelerating activity of complement receptor type 1 (CD35) - Two active sites are required for dissociating C5 convertases [J].
Krych-Goldberg, M ;
Hauhart, RE ;
Subramanian, VB ;
Yurcisin, BM ;
Crimmins, DL ;
Hourcade, DE ;
Atkinson, JP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (44) :31160-31168
[9]  
Lambris JD, 1996, J IMMUNOL, V156, P4821
[10]   Cloning of Z39Ig, a novel gene with immunoglobulin-like domains located on human chromosome X [J].
Langnaese, K ;
Colleaux, L ;
Kloos, DU ;
Fontes, M ;
Wieacker, P .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2000, 1492 (2-3) :522-525